Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

August 16, 2021 08:05 ET | Source: ARCA biopharma, Inc.

ARCA biopharma to Present at the Q3 Virtual Investor Summit on August 18th

WESTMINSTER, Colo., Aug. 16, 2021 (GLOBE NEWSWIRE) -- ARCA biopharma, Inc. (Nasdaq: ABIO), a biopharmaceutical company applying a precision medicine approach to developing genetically targeted...
May 05, 2021 16:05 ET | Source: ARCA biopharma, Inc.

Christopher Graybill Joins ARCA as Vice President, Clinical Development

WESTMINSTER, Colo., May 05, 2021 (GLOBE NEWSWIRE) -- ARCA biopharma, Inc. (Nasdaq: ABIO), a biopharmaceutical company applying a precision medicine approach to developing genetically targeted...
May 06, 2020 16:30 ET | Source: ARCA biopharma, Inc.

ARCA Biopharma Announces First Quarter 2020 Financial Results And Provides Corporate Update

U.S. FDA Special Protocol Assessment agreement for PRECISION-AF, a single pivotal Phase 3 clinical trial of genetically targeted GencaroPRECISION-AF trial to evaluate Gencaro as a potential treatment...
August 01, 2019 16:30 ET | Source: ARCA biopharma, Inc.

ARCA biopharma Announces Second Quarter 2019 Financial Results and Provides Corporate Update

FDA SPA Agreement for Phase 3 atrial fibrillation trial (PRECISION-AF) amended to expand patient population to include heart failure patients with preserved ejection fraction (HFpEF)PRECISION-AF...
May 08, 2019 16:30 ET | Source: ARCA biopharma, Inc.

ARCA Biopharma Announces First Quarter 2019 Financial Results and Provides Corporate Update

WESTMINSTER, Colo., May 08, 2019 (GLOBE NEWSWIRE) -- ARCA biopharma, Inc. (Nasdaq: ABIO), a biopharmaceutical company applying a precision medicine approach to developing genetically-targeted...
March 18, 2019 08:30 ET | Source: ARCA biopharma, Inc.

Identification of Phosphodiesterease 3A Polymorphism With Potential to Increase Effectiveness of PDE3 Inhibitors Published in the Journal of the American College of Cardiology

WESTMINSTER, Colo., March 18, 2019 (GLOBE NEWSWIRE) -- ARCA biopharma, Inc. (Nasdaq: ABIO), a biopharmaceutical company applying a precision medicine approach to developing genetically-targeted...
February 27, 2019 16:15 ET | Source: ARCA biopharma, Inc.

ARCA biopharma Announces Fiscal Year 2018 Financial Results and Provides Corporate Update

WESTMINSTER, Colo., Feb. 27, 2019 (GLOBE NEWSWIRE) -- ARCA biopharma, Inc. (Nasdaq: ABIO), a biopharmaceutical company applying a precision medicine approach to developing genetically-targeted...
November 12, 2018 08:30 ET | Source: ARCA biopharma, Inc.

GENETIC-AF Phase 2B Clinical Trial Atrial Fibrillation Burden (AFB) Results Presented at American Heart Association 2018 Scientific Sessions

AF detection by implanted Medtronic devicesSimilar trends for benefit in favor of Gencaro compared to active comparator for AF risk reduction observed by continuous monitoring with implanted devices...
May 08, 2018 16:15 ET | Source: ARCA biopharma, Inc.

ARCA Biopharma announces first quarter 2018 financial results AND Provides Corporate Update

WESTMINSTER, Colo., May 08, 2018 (GLOBE NEWSWIRE) -- ARCA biopharma, Inc. (Nasdaq:ABIO), a biopharmaceutical company applying a precision medicine approach to developing genetically-targeted...
January 08, 2018 08:30 ET | Source: ARCA biopharma, Inc.

ARCA biopharma Announces Completion of GENETIC-AF Phase 2B Clinical Trial

-------------------------------------------------------------------------------------------------- GENETIC-AF Evaluating Gencaro as Potentially First Genetically-Targeted Treatment for Atrial...

Next Page keyboard_arrow_right